Durvalumab, Cediranib ± Olaparib in Recurrent Ovarian Cancer
In a groundbreaking phase II proof-of-concept clinical trial published recently in Nature Communications, researchers led by Tabata, Huang, and Giudice ...
In a groundbreaking phase II proof-of-concept clinical trial published recently in Nature Communications, researchers led by Tabata, Huang, and Giudice ...
In the relentless battle against recurrent ovarian cancer, researchers are exploring innovative approaches beyond the traditional chemotherapy regimens that have ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine